Evidence map›Paper›PMID 36115594›Full record

ArticleJournal of lipid research2022

1-Deoxysphingolipid synthesis compromises anchorage-independent growth and plasma membrane endocytosis in cancer cells.

Thekla Cordes, Ramya S Kuna, Grace H McGregor, Sanika V Khare, Jivani Gengatharan, Thangaselvam Muthusamy, Christian M Metallo

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of lipid research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
2.1field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 27 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Genetic Background of Macular Telangiectasia Type 2.International journal of molecular sciences · 2025
    Review
  8. Article
  9. Review
  10. Review
  11. Review
  12. Review
  13. Review
  14. Article
  15. Article
  16. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 2 countries.

Thekla CordesDepartment of Bioengineering, University of California, San Diego, La Jolla, CA, USA; Molecular and Cell Biology Laboratory, Salk Institute for Biological Studies, La Jolla, CA, USA; Department of Bioinformatics and Biochemistry, Braunschweig Integrated Centre of Systems Biology (BRICS), Technische Universität Braunschweig, Braunschweig, Germany.
Ramya S KunaDepartment of Bioengineering, University of California, San Diego, La Jolla, CA, USA; Molecular and Cell Biology Laboratory, Salk Institute for Biological Studies, La Jolla, CA, USA.
Grace H McGregorDepartment of Bioengineering, University of California, San Diego, La Jolla, CA, USA; Molecular and Cell Biology Laboratory, Salk Institute for Biological Studies, La Jolla, CA, USA.
Sanika V KhareDepartment of Bioengineering, University of California, San Diego, La Jolla, CA, USA; Molecular and Cell Biology Laboratory, Salk Institute for Biological Studies, La Jolla, CA, USA.
Jivani GengatharanDepartment of Bioengineering, University of California, San Diego, La Jolla, CA, USA; Molecular and Cell Biology Laboratory, Salk Institute for Biological Studies, La Jolla, CA, USA.
Thangaselvam MuthusamyDepartment of Bioengineering, University of California, San Diego, La Jolla, CA, USA.
Christian M MetalloDepartment of Bioengineering, University of California, San Diego, La Jolla, CA, USA; Molecular and Cell Biology Laboratory, Salk Institute for Biological Studies, La Jolla, CA, USA. Electronic address: metallo@salk.edu.
Salk Institute for Biological Studies · USUniversity of California San Diego · US

Funding

Viral Vector Core (VVC)P30CA014195 · NCI · SALK INSTITUTE FOR BIOLOGICAL STUDIES · PI Reuben Shaw · 1985 to 2026
$82.8M
Non-essential amino acids and sphingolipid diversity in cancer progressionR01CA234245 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI METALLO, CHRISTIAN MICHAEL · 2019 to 2023
$1.9M
Identifying and exploiting metabolic vulnerabilities in cancer using mass spectrometry and tracing approachesR50CA252146 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI CORDES, THEKLA · 2021 to 2021
$168k
NCI NIH HHS P30 CA014195NCI NIH HHS R01 CA234245NCI NIH HHS R50 CA252146
6 · The paper itself

Abstract

Serine palmitoyltransferase (SPT) predominantly incorporates serine and fatty acyl-CoAs into diverse sphingolipids (SLs) that serve as structural components of membranes and signaling molecules within or amongst cells. However, SPT also uses alanine as a substrate in the contexts of low serine availability, alanine accumulation, or disease-causing mutations in hereditary sensory neuropathy type I, resulting in the synthesis and accumulation of 1-deoxysphingolipids (deoxySLs). These species promote cytotoxicity in neurons and impact diverse cellular phenotypes, including suppression of anchorage-independent cancer cell growth. While altered serine and alanine levels can promote 1-deoxySL synthesis, they impact numerous other metabolic pathways important for cancer cells. Here, we combined isotope tracing, quantitative metabolomics, and functional studies to better understand the mechanistic drivers of 1-deoxySL toxicity in cancer cells. We determined that both alanine treatment and SPTLC1

Indexed as

NeoplasmsSerine C-PalmitoyltransferaseAgarAlanineCell MembraneCeramidesEndocytosisMetabolic Networks and PathwaysSerineSphingolipids1-deoxysphingolipidAgarAlanineCeramidesSerineSerine C-PalmitoyltransferaseSphingolipids1-deoxy(dihydro)ceramide1-deoxysphingolipid accumulationalaninemetabolismmitochondrial stressRAB5serineserine palmitoyltransferasesoft agarSPT promiscuity

Identifiers

PMID36115594
PMCPMC9587408
OpenAlexW4295963273

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.